SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

EIQ (EIQ) News

Follow EIQ (EIQ) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 15 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol EIQ Asset equity Sector Markets 90 days 15 Updated Sep 17, 2026, 01:05 AM UTC Open live news feed Open EIQ chart & news
L EchoIQ says FDA raises no concerns about Echosolv HF technology EchoIQ Ltd says the FDA raised no concerns about its Echosolv HF technology or core functionality. REGULATION | Sep 17, 2026, 01:05 AM UTC L Shaw & Partners cuts Echo IQ price target 53% to A$0.70 EQUITY | Sep 10, 2026, 12:07 AM UTC L Bell Potter downgrades Echo IQ to speculative sell EQUITY | Sep 09, 2026, 11:13 PM UTC L Bell Potter cuts Echo IQ price target 83% to A$0.30 EQUITY | Sep 09, 2026, 11:13 PM UTC L Morgans cuts Echo IQ price target 41% to A$1.10 Morgans cut its price target for Echo IQ by 41% to A$1.10 per share. EQUITY | Sep 09, 2026, 11:03 PM UTC L Echo IQ reviews regulatory options after FDA non-substantially equivalent 510(k) Echo IQ (EIQ) is reviewing its regulatory options after the FDA issued a not substantially equivalent determination for its initial EchoSolv HF 510(k) application. The product is not cleared for commercial use at this ti REGULATION | Sep 09, 2026, 02:46 AM UTC M EIQ FDA NSE letter delays heart failure solution timeline EIQ said an FDA NSE letter for its heart failure solution delayed progress but did not derail it. Management is pursuing multiple regulatory pathways and maintaining high FDA engagement, supported by financial strength a REGULATION | Sep 08, 2026, 11:28 PM UTC L Echo IQ seen facing selloff after FDA clearance denial Petra Capital says Echo IQ shares are likely to be sold today after the U.S. FDA didn’t clear its EchoSolv HF heart-failure detection tool. The regulator issued a Not Substantially Equivalent determination. REGULATION | Sep 08, 2026, 10:39 PM UTC L Echo IQ downgraded to Sell from Hold by Petra Capital Echo IQ was downgraded to Sell from Hold by Petra Capital. EQUITY | Sep 08, 2026, 10:30 PM UTC M FDA delays EchoSolv HF 510(k) clearance for EchoIQ FDA has not cleared the initial EchoSolv HF 510(k) application, prompting a review of regulatory options. EchoIQ says business momentum remains strong, supported by cash reserves and ongoing US commercial expansion. REGULATION | Sep 08, 2026, 10:23 PM UTC L EchoIQ requests trading halt EchoIQ Ltd has requested a trading halt on ASX. EQUITY | Sep 07, 2026, 01:38 AM UTC L EchoIQ appoints Scott Wilkin as non-executive director EchoIQ appoints Scott Wilkin as non-executive director. EQUITY | Sep 01, 2026, 01:32 AM UTC L Shaw & Partners cuts EchoIQ price target 25% to A$1.50 Shaw & Partners cut its EchoIQ price target by 25% to A$1.50 per share. EQUITY | Aug 30, 2026, 10:32 PM UTC L EchoIQ downgraded to Hold from Buy by Shaw & Partners Shaw & Partners downgraded EchoIQ to Hold from Buy, according to TradingView News. EQUITY | Aug 30, 2026, 10:32 PM UTC M EIQ net loss widens to $18.6m EIQ reported net loss widened to $18.6m as US expansion accelerated and capital was raised for future growth. EQUITY | Aug 28, 2026, 05:29 AM UTC